A detailed history of Gds Wealth Management transactions in Astrazeneca PLC stock. As of the latest transaction made, Gds Wealth Management holds 5,709 shares of AZN stock, worth $366,860. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,709
Previous 6,157 7.28%
Holding current value
$366,860
Previous $480,000 7.5%
% of portfolio
0.04%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$76.67 - $87.62 $34,348 - $39,253
-448 Reduced 7.28%
5,709 $444,000
Q2 2024

Aug 09, 2024

SELL
$66.81 - $80.83 $7,282 - $8,810
-109 Reduced 1.74%
6,157 $480,000
Q1 2024

Apr 24, 2024

SELL
$61.03 - $69.57 $5,919 - $6,748
-97 Reduced 1.52%
6,266 $424,000
Q4 2023

Feb 06, 2024

SELL
$61.89 - $69.28 $4,703 - $5,265
-76 Reduced 1.18%
6,363 $428,000
Q3 2023

Oct 19, 2023

SELL
$64.85 - $71.7 $51,490 - $56,929
-794 Reduced 10.98%
6,439 $436,000
Q2 2023

Jul 27, 2023

SELL
$69.91 - $75.81 $629 - $682
-9 Reduced 0.12%
7,233 $517,000
Q1 2023

May 10, 2023

SELL
$63.15 - $71.6 $7,893 - $8,950
-125 Reduced 1.7%
7,242 $502,000
Q4 2022

Jan 26, 2023

SELL
$54.21 - $70.44 $2,385 - $3,099
-44 Reduced 0.59%
7,367 $0
Q3 2022

Oct 20, 2022

BUY
$53.02 - $135.75 $2,332 - $5,973
44 Added 0.6%
7,411 $406,000
Q2 2022

Aug 05, 2022

SELL
$59.26 - $71.14 $177 - $213
-3 Reduced 0.04%
7,367 $487,000
Q1 2022

Aug 05, 2022

SELL
$55.72 - $67.12 $87,034 - $104,841
-1,562 Reduced 17.49%
7,370 $506,000
Q4 2021

Aug 05, 2022

BUY
$54.02 - $63.83 $482,506 - $570,129
8,932 New
8,932 $520,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $199B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Gds Wealth Management Portfolio

Follow Gds Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gds Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Gds Wealth Management with notifications on news.